| Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer | Science advances |  | | 2025 | 78 | 154 |
|
| Convergent inducers and effectors of T cell paralysis in the tumour microenvironment | Nature reviews. Cancer |  | | 2025 | 36 | 0 |
|
| Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy : results of SAKK 11/16, a phase IIa trial | Experimental hematology & oncology | | | 2025 | 41 | 25 |
|
| The current landscape of spatial biomarkers for prediction of response to immune checkpoint inhibition | npj precision oncology | | | 2024 | 67 | 22 |
|
| Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy | Cell | | | 2024 | 936 | 228 |
|
| Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma | Science immunology | | | 2024 | 259 | 0 |
|
| SwissDock 2024: major enhancements for small-molecule docking with Attracting Cavities and AutoDock Vina | Nucleic acids research | | | 2024 | 1 | 0 |
|
| LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy | ESMO Congress 2023 | | | 2023 | 115 | 65 |
|
| Testing a model of care for patients on immune checkpoint inhibitors based on electronic patient-reported outcomes : protocol for a randomized phase II controlled trial | JMIR research protocols | | | 2023 | 111 | 107 |
|
| Neoadjuvant immunotherapy : a promising new standard of care | International journal of molecular sciences | | | 2023 | 105 | 109 |
|
| Novel targets for immune-checkpoint inhibition in cancer | Cancer treatment reviews | | | 2023 | 89 | 52 |
|
| Dendritic cells direct circadian anti-tumour immune responses | Nature | | | 2023 | 768 | 184 |
|
| Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient | Cancer biology & therapy | | | 2023 | 88 | 29 |
|
| Towards a national strategy for digital pathology in Switzerland | Virchows Archiv | | | 2022 | 234 | 59 |
|
| Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab | Gynecologic Oncology Reports | | | 2021 | 258 | 109 |
|
| The Peroxisomal Enzyme L-PBE Is Required to Prevent the Dietary Toxicity of Medium-Chain Fatty Acids | Cell Reports | | | 2013 | 271 | 100 |
|
| T cell recognition of hapten. Anatomy of T cell receptor binding of a H-2kd-associated photoreactive peptide derivative | The Journal of biological chemistry | | | 1999 | 1 | 0 |
|
